BR112019003175A2 - métodos para determinar o potencial de uma proteína para se auto-associar e para preparar uma formulação farmacêutica de baixa viscosidade contendo uma proteína, e, mistura bioanalítica. - Google Patents
métodos para determinar o potencial de uma proteína para se auto-associar e para preparar uma formulação farmacêutica de baixa viscosidade contendo uma proteína, e, mistura bioanalítica.Info
- Publication number
- BR112019003175A2 BR112019003175A2 BR112019003175-8A BR112019003175A BR112019003175A2 BR 112019003175 A2 BR112019003175 A2 BR 112019003175A2 BR 112019003175 A BR112019003175 A BR 112019003175A BR 112019003175 A2 BR112019003175 A2 BR 112019003175A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- self
- methods
- bioanalytical
- associate
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N2021/258—Surface plasmon spectroscopy, e.g. micro- or nanoparticles in suspension
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376788P | 2016-08-18 | 2016-08-18 | |
| US62/376788 | 2016-08-18 | ||
| PCT/US2017/047630 WO2018035470A1 (en) | 2016-08-18 | 2017-08-18 | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019003175A2 true BR112019003175A2 (pt) | 2019-06-18 |
Family
ID=59746357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019003175-8A BR112019003175A2 (pt) | 2016-08-18 | 2017-08-18 | métodos para determinar o potencial de uma proteína para se auto-associar e para preparar uma formulação farmacêutica de baixa viscosidade contendo uma proteína, e, mistura bioanalítica. |
Country Status (19)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11428695B2 (en) | 2016-08-18 | 2022-08-30 | Regeneron Pharmaceuticals, Inc. | Concentration-dependent self-interaction assay |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| CN113588582B (zh) * | 2020-04-30 | 2024-05-14 | 上海药明生物技术有限公司 | 蛋白质样品浓度测定方式选择法及测定方法 |
| WO2023095154A1 (en) * | 2021-11-24 | 2023-06-01 | Sensoville Biotech Pvt Ltd | Method for determining changes in a protein's structure |
| AU2023208644A1 (en) * | 2022-01-24 | 2024-07-04 | Amgen Inc. | Methods for detecting antibody self-association |
| CN119832975A (zh) * | 2024-12-24 | 2025-04-15 | 上海药明生物技术有限公司 | 一种蛋白质共处方制剂的稳定性预测方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US771997A (en) | 1903-11-21 | 1904-10-11 | Alfred Palm | Lathe attachment. |
| US4254102A (en) * | 1975-09-08 | 1981-03-03 | Plough, Inc. | Substantive PABA compositions |
| US4080264A (en) | 1976-03-01 | 1978-03-21 | Massachusetts Institute Of Technology | Immunoassay by light scattering spectroscopy |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US20050214356A1 (en) * | 2004-03-24 | 2005-09-29 | Joyce Timothy H | Self assembling activation agents targeted using active drug release |
| US20050221507A1 (en) * | 2004-03-30 | 2005-10-06 | Intel Corporation | Method to detect molecular binding by surface-enhanced Raman spectroscopy |
| US7514938B2 (en) | 2004-05-11 | 2009-04-07 | Board Of Regents Of The University And College System Of Nevada, On Behalf Of The University Of Nevada, Reno | Dielectric relaxation spectroscopy apparatus and methods of use |
| TW200621282A (en) * | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
| ES2352509T3 (es) * | 2005-05-02 | 2011-02-21 | Baseclick Gmbh | Nuevas estrategias de marcaje para la detección sensible de analitos. |
| US20070291265A1 (en) | 2006-04-13 | 2007-12-20 | Mississippi State University | Optical apparatus for simultaneously measuring the scattering and concentration of signals of macromolecules in a flow cell |
| KR20090069330A (ko) * | 2006-10-12 | 2009-06-30 | 와이어쓰 | 유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화 |
| GB0621050D0 (en) * | 2006-10-23 | 2006-11-29 | Univ Strathclyde | Functionalised polymers for labelling metal surfaces |
| DK2150617T3 (en) | 2007-06-04 | 2015-01-12 | Regeneron Pharma | Regions with increased expression and stability |
| JP2011520769A (ja) * | 2007-09-21 | 2011-07-21 | サイトイミューン サイエンシズ インコーポレイテッド | ナノ治療コロイド金属組成物および方法 |
| WO2010059963A2 (en) | 2008-11-21 | 2010-05-27 | The Board Of Regents Of The University Of Texas System | Preparation and methodology of silk fibroin nanoparticles |
| US20140024024A1 (en) * | 2012-07-17 | 2014-01-23 | General Electric Company | Methods of detecting dna, rna and protein in biological samples |
| JP6099108B2 (ja) | 2013-05-30 | 2017-03-29 | 公立大学法人大阪府立大学 | 被検出物質の検出装置および方法 |
| IL312865B2 (en) * | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| EP2902503A1 (en) * | 2014-01-31 | 2015-08-05 | Fundación Imdea Nanociencia | Functionalized metal nanoparticles and uses thereof for detecting nucleic acids |
| WO2015196091A1 (en) * | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| CN104062287B (zh) * | 2014-07-01 | 2017-08-08 | 福建工程学院 | 一种基于纳米金催化的化学发光分析检测铁蛋白的方法 |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| WO2016115475A1 (en) | 2015-01-18 | 2016-07-21 | Biogen Ma Inc. | Anti-cd40 antibody formulations |
| EA201990316A1 (ru) | 2016-08-18 | 2019-07-31 | Ридженерон Фармасьютикалз, Инк. | Анализ для определения потенциала самоассоциации белка с использованием концентрационно-зависимой спектроскопии самовзаимодействия на основе наночастиц |
-
2017
- 2017-08-18 EA EA201990316A patent/EA201990316A1/ru unknown
- 2017-08-18 KR KR1020197006376A patent/KR102441221B1/ko not_active Expired - Fee Related
- 2017-08-18 EP EP20191942.0A patent/EP3761035B1/en active Active
- 2017-08-18 PL PL17761159T patent/PL3500856T3/pl unknown
- 2017-08-18 CA CA3254460A patent/CA3254460A1/en active Pending
- 2017-08-18 KR KR1020227030436A patent/KR102534506B1/ko active Active
- 2017-08-18 EP EP17761159.7A patent/EP3500856B1/en active Active
- 2017-08-18 WO PCT/US2017/047630 patent/WO2018035470A1/en not_active Ceased
- 2017-08-18 DK DK17761159.7T patent/DK3500856T3/da active
- 2017-08-18 MX MX2019001930A patent/MX2019001930A/es unknown
- 2017-08-18 DK DK20191942.0T patent/DK3761035T3/da active
- 2017-08-18 CN CN202211108451.8A patent/CN115468919A/zh active Pending
- 2017-08-18 HU HUE17761159A patent/HUE052805T2/hu unknown
- 2017-08-18 CA CA3254461A patent/CA3254461A1/en active Pending
- 2017-08-18 US US16/326,238 patent/US11428695B2/en active Active
- 2017-08-18 IL IL264640A patent/IL264640B2/en unknown
- 2017-08-18 ES ES20191942T patent/ES2974961T3/es active Active
- 2017-08-18 SG SG11201900895QA patent/SG11201900895QA/en unknown
- 2017-08-18 AU AU2017313150A patent/AU2017313150B2/en active Active
- 2017-08-18 JP JP2019508809A patent/JP6959327B2/ja not_active Expired - Fee Related
- 2017-08-18 HU HUE20191942A patent/HUE066064T2/hu unknown
- 2017-08-18 KR KR1020237016537A patent/KR102717462B1/ko active Active
- 2017-08-18 IL IL307435A patent/IL307435A/en unknown
- 2017-08-18 FI FIEP20191942.0T patent/FI3761035T3/fi active
- 2017-08-18 CA CA3032361A patent/CA3032361C/en active Active
- 2017-08-18 CN CN201780050825.6A patent/CN109661577B/zh active Active
- 2017-08-18 PL PL20191942.0T patent/PL3761035T3/pl unknown
- 2017-08-18 ES ES17761159T patent/ES2837093T3/es active Active
- 2017-08-18 BR BR112019003175-8A patent/BR112019003175A2/pt not_active Application Discontinuation
-
2019
- 2019-02-15 MX MX2023013583A patent/MX2023013583A/es unknown
- 2019-02-18 ZA ZA2019/01035A patent/ZA201901035B/en unknown
-
2021
- 2021-10-07 JP JP2021165510A patent/JP7321227B2/ja active Active
-
2022
- 2022-07-20 US US17/868,983 patent/US11988668B2/en active Active
-
2023
- 2023-07-25 JP JP2023120438A patent/JP2023139189A/ja active Pending
- 2023-12-04 AU AU2023274236A patent/AU2023274236A1/en not_active Abandoned
-
2024
- 2024-04-16 US US18/637,055 patent/US20240280582A1/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11428695B2 (en) | 2016-08-18 | 2022-08-30 | Regeneron Pharmaceuticals, Inc. | Concentration-dependent self-interaction assay |
| US11988668B2 (en) | 2016-08-18 | 2024-05-21 | Regeneron Pharmaceuticals, Inc. | Concentration-dependent self-interaction assay |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201901035B (en) | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy | |
| BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
| BR112019005328A2 (pt) | composição farmacêutica líquida | |
| BR112012022223A2 (pt) | formulações de proteína concentrada e usos das mesmas | |
| CL2018003178A1 (es) | Composición farmacéutica | |
| BR112016029906A8 (pt) | formulação líquida, uso de formulação terapêutica líquida, uso de formulação terapêutica líquida injetável, método de melhoria da estabilidade de uma formulação proteica líquida e método de melhoria de um processo relacionado a proteínas | |
| BR112017003419A2 (pt) | formulação de anticorpo anti-il-4r-alfa estável | |
| EA201592302A1 (ru) | Способы снижения уровня остаточного холестерина и других фракций липопротеинов путем введения ингибитора пропротеиновой конвертазы субтилизин-кексинового типа 9 (pcsk9) | |
| BR112018075516A2 (pt) | purificação de anticorpos multiespecíficos | |
| CL2020002805A1 (es) | Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526) | |
| BR112017008161A2 (pt) | método para preparação de uma composição de lisolecitina, composição de lisolecitina, emulsão flavorizante, e, bebida líquida ou concentrado de bebida líquida. | |
| BR112016014756A8 (pt) | formulação de selante compreendendo fibrinogênio e zimogênios, seu método de fabricação, recipiente e uso | |
| GT201700184A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
| MX2015012862A (es) | Moleculas de union para bcma y cd3. | |
| UY36178A (es) | Novedosos derivados de ácido heteroaril-butanoico | |
| AR112536A1 (es) | Métodos para reducir la formación de partículas y composiciones elaboradas a través de los mismos | |
| BR112017010078A2 (pt) | composições, dispositivos e métodos de teste de sensibilidade de ibs | |
| BR112017001860A2 (pt) | peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal | |
| BR112018012183A2 (pt) | composição cosmética e seu uso, formulação cosmética | |
| CL2021000635A1 (es) | Composición sólida que comprende un componente oleoso comprendiendo uno o más aceites y un componente lipídico comprendiendo uno o más lípidos; su método de preparación (div. sol. 202000918). | |
| BR112017004412A2 (pt) | método para medir reatividade de fviii | |
| BR112016001919A2 (pt) | composição cosmética e processo de tratamento cosmético | |
| BR112022004563A2 (pt) | Coliberação de sirna tgf-ß e sirna pdl1 para tratar câncer | |
| CL2016001375A1 (es) | Composición, que comprende agente bioactivo (inmunógeno) dispersado en gotitas de aceite, polímero de recubrimiento entérico, un polímero mucoadhesivo, su método de preparación y uso para la administración oral de un agente bioactivo. | |
| AR107782A1 (es) | Formulación gonadotropina líquida estable |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023012318-2 PROTOCOLO 870230052901 EM 20/06/2023 16:54. |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |